Schizophrenia Clinical Trial
Official title:
Does Cognitive Behavioral Therapy Improve Depressive Symptoms and Self-Esteem in Patients With a First Episode Psychosis? A Randomized Controlled Study
The purpose of the present study is to examine whether cognitive behavior therapy will reduce depressive symptoms and increase self-esteem for patients with a first episode psychosis.
A growing body of evidence supports the use of Cognitive Behavioural Therapy (CBT) for the
treatment of schizophrenia. The strength of evidence is especially strong for patients with
persistent hallucinations and delusions. As it comes to the effect of CBT for patients with
a first episode psychosis the picture is more unclear. The main reason is probably that the
CBT interventions to a less extent have been adjusted to fit first episode psychosis
patients. The main problems for patients with a first episode psychosis (FEP) is rarely
persistent hallucinations and delusions but they struggle with social anxiety, depression,
alcohol and drug abuse and low self esteem. Forthcoming studies examining the effect of CBT
for patients with a first episode psychosis should aim to have a focus on these symptoms.
The main aim of the present study is to examine whether CBT has any effect on depressive
symptoms and self-esteem in patients with a FEP.
The study will include patients with a first episode psychosis with Axis-I DSM IV diagnosis
of schizophrenia, schizoaffective disorder, delusional disorder, and psychosis not otherwise
specified. To be included in the study the patients should meet the criteria of an affective
episode the last year or have a score on Calgary Depression of Schizophrenia Scale above
four. Patients are randomly selected to either a treatment group or a control (placebo)
group. The aim is to include 30 patients in each group. Patients in the treatment group will
receive a manual-based CBT intervention comprising up to 26 sessions during a six months
period. The control group will receive treatment as usual (TAU).
The patients are assessed before the entry of the study and after 6 months (end of
treatment). Moreover they will be assessed after 9 months of ending therapy.
Hypothesis:
In this study we hypothesize that
- patients receiving CBT will have less depressive symptoms than TAU-patients at the and
of treatment and at six months follow up
- CBT-patients will demonstrate a better improvement in their self-esteem than
TAU-patients at the end of treatment and at six months follow up.
To our knowledge, no previous studies have examined outcome after CBT treatment with regards
to depressive symptoms and self-esteem. Furthermore, this is the first randomized controlled
study in Norway of CBT among patients with a FEP.
;
Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |